REDUCE-IT Post-Hoc Analysis: Icosapent Ethyl Lowers Events in 8,179 Extreme Risk Patients
At ACC Scientific Sessions 2026, Amarin-supported analysis of 8,179 REDUCE-IT trial participants at extreme cardiovascular risk showed icosapent ethyl reduced events vs placebo; poster data indicated EPA inhibits lipoprotein(a) oxidation. Updated 2026 ACC/AHA dyslipidemia guidelines now highlight elevated triglycerides as a residual risk factor and endorse complementary therapies beyond statins.
1. ACC Sessions Highlights Icosapent Ethyl Efficacy
At the American College of Cardiology Scientific Sessions 2026, Amarin presented a post hoc analysis of the REDUCE-IT trial involving 8,179 statin-treated patients with maintained LDL-C control and elevated triglycerides. The analysis demonstrated that adding icosapent ethyl on top of statin therapy significantly reduced composite cardiovascular events in both extreme and very high-risk cohorts.
2. Updated 2026 Dyslipidemia Guidelines Emphasize TG
The newly released 2026 ACC/AHA/Multi-society Dyslipidemia Guidelines now recognize elevated triglycerides as a meaningful contributor to residual cardiovascular risk even after LDL-C targets are met, and they endorse complementary therapies beyond statin monotherapy for high and very high-risk patients.
3. Mechanistic and Plaque Data Support EPA Benefits
Amarin-supported poster data showed that EPA inhibits lipoprotein(a) oxidation at elevated levels, suggesting benefits beyond triglyceride reduction. Prior plaque imaging studies such as EVAPORATE and CHERRY have linked EPA therapy to favorable coronary plaque changes, reinforcing mechanistic evidence underpinning the clinical outcomes seen in REDUCE-IT.